Kidney disease and cardiovascular disease: Implications of dyslipidemia

Cardiology Clinics

Volumn 23, Issue 3, 2005, Pages 363-372

  Keane, William F ^a   Lyle, Paulette A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MINERAL; SIMVASTATIN; VITAMIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DISEASE SEVERITY; DYSLIPIDEMIA; EXERCISE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PATIENT; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; LIPIDS; RENAL DIALYSIS;

EID: 23244433986     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2005.03.004     Document Type: Review

References (100)

1. US Renal Data System USRDS 1998 annual data report 1998 National Institutes of Health National Institute of Diabetes Bethesda
2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 1 2002 S1 S266
3. P.J. Watkins Cardiovascular disease, hypertension, and lipids BMJ 326 7394 2003 874 876
4. P. Jungers, Z.A. Massy, and T.N. Khoa Incidence and risks of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study Nephrol Dial Transplant 12 12 1997 2597 2602
5. R.N. Foley, P.S. Parfrey, and J.D. Harnett Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 1 1995 186 192
6. A.S. Levey, J.A. Beto, and B.E. Coronado Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 5 1998 853 906
7. R.N. Foley, P.S. Parfrey, and D. Hefferton Advance prediction of early death in patients starting maintenance dialysis Am J Kidney Dis 23 6 1994 836 845
8. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 17 2003 2154 2169
9. B.F. Culleton, M.G. Larson, and P.W. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 6 1999 2214 2219
10. N.B. Shulman, C.E. Ford, and W.D. Hall Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 Suppl 5 1989 I80 I93
11. L.M. Ruilope, A. Salvetti, and K. Jamerson Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study J Am Soc Nephrol 12 2 2001 218 225
12. F. Locatelli, L. Del Vecchio, and P. Pozzoni The importance of early detection of chronic kidney disease Nephrol Dial Transplant 17 Suppl 11 2002 2 7
13. H.L. Hillege, W.M. Janssen, and A.A. Bak Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity J Intern Med 249 6 2001 519 526
14. S. Romundstad, J. Holmen, and H. Hallan Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trondelag Health Study (HUNT, 1995-97), Norway J Intern Med 252 2 2002 164 172
15. J.S. Yudkin, R.D. Forrest, and C.A. Jackson Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey Lancet 2 8610 1988 530 533
16. S.F. Dinneen, and H.C. Gerstein The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature Arch Intern Med 157 13 1997 1413 1418
17. H.C. Gerstein, J.F. Mann, Q. Yi, and B. Zinman Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 4 2001 421 426
18. H.L. Hillege, V. Fidler, and G.F. Diercks Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population Circulation 106 14 2002 1777 1782
19. P. Rossing, P. Hougaard, and K. Borch-Johnsen Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study BMJ 313 7060 1996 779 784
20. A. Jager, P.J. Kostense, and H.G. Ruhe Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study Arterioscler Thromb Vasc Biol 19 3 1999 617 624
21. E.M. Damsgaard, A. Froland, and O.D. Jorgensen Microalbuminuria as predictor of increased mortality in elderly people BMJ 300 6720 1990 297 300
22. M. Roest, J.D. Banga, and W.M. Janssen Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women Circulation 103 25 2001 3057 3061
23. K. Borch-Johnsen, B. Feldt-Rasmussen, and S. Strandgaard Urinary albumin excretion. An independent predictor of ischemic heart disease Arterioscler Thromb Vasc Biol 19 8 1999 1992 1997
24. H.C. Gerstein, J.F. Mann, and J. Pogue Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators Diabetes Care 23 Suppl 2 2000 B35 B39
25. P.H. Winocour, J.O. Harland, and J.P. Millar Microalbuminuria and associated cardiovascular risk factors in the community Atherosclerosis 93 1-2 1992 71 81
26. M.S. Goligorsky, J. Chen, and S. Brodsky Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide Hypertension 37 2 Part 2 2001 744 748
27. R.H. Grimm Jr., K.H. Svendsen, and B. Kasiske Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial Kidney Int 52 Suppl 63 1997 S10 S14
28. R.G. Nelson, D.J. Pettitt, and M.J. Carraher Effect of proteinuria on mortality in NIDDM Diabetes 37 11 1988 1499 1504
29. D.J. Ballard, L.L. Humphrey, and L.J. Melton III Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota Diabetes 37 4 1988 405 412
30. J.M. Stephenson, S. Kenny, and L.K. Stevens Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes Diabet Med 12 2 1995 149 155
31. K. Harris, M. Thomas, and C. Short Assessment of the efficacy of treatment of dyslipidaemia in renal outpatients J Nephrol 15 3 2002 263 269
32. B.L. Kasiske Hyperlipidemia in patients with chronic renal disease Am J Kidney Dis 32 5 Suppl 3 1998 S142 S156
33. P.O. Attman Progression of renal failure and lipids: is there evidence for a link in humans? Nephrol Dial Transplant 13 3 1998 545 547
34. V.S. Kamanna, D.D. Roh, and M.A. Kirschenbaum Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus Histol Histopathol 13 1 1998 169 179
35. E.D. Crook, A. Thallapureddy, and S. Migdal Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 325 6 2003 340 348
36. B. Kasiske, F.G. Cosio, and J. Beto Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Am J Transplant 4 Suppl 7 2004 13 53
37. H. Mulec, S.A. Johnsen, and O. Wiklund Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22 1 1993 196 201
38. M. Washio, S. Okuda, and M. Ikeda Hypercholesterolemia and the progression of the renal dysfunction in chronic renal failure patients J Epidemiol 6 4 1996 172 177
39. 1c, cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population Am J Kidney Dis 36 2 2000 272 281
40. H. Yokoyama, O. Tomonaga, and M. Hirayama Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients Diabetologia 40 4 1997 405 411
41. P. Cappelli, M. Evangelista, and M. Bonomini Lipids in the progression of chronic renal failure Nephron 62 1 1992 31 35
42. O. Samuelsson, M. Aurell, and C. Knight-Gibson Apolipoprotein-B- containing lipoproteins and the progression of renal insufficiency Nephron 63 3 1993 279 285
43. A.S. Krolewski, J.H. Warram, and A.R. Christlieb Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy Kidney Int 45 Suppl 45 1994 S125 S131
44. M. Ravid, L. Neumann, and M. Lishner Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors Kidney Int 47 3 1995 907 910
45. M. Mänttäri, E. Tiula, and T. Alikoski Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 4 1995 670 675
46. O. Wirta, A. Pasternack, and P. Laippala Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects Clin Nephrol 45 1 1996 10 17
47. M.J. Klag, P.K. Whelton, and B. Randall Serum cholesterol and ESRD incidence in men screened for the MRFIT [abstract] J Am Soc Nephrol 6 1996 393
48. L.G. Hunsicker, S. Adler, and A. Caggiula Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 6 1997 1908 1919
49. G. Manjunath, H. Tighiouart, and H. Ibrahim Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J Am Coll Cardiol 41 1 2003 47 55
50. V.M. Campese, S. Bianchi, and R. Bigazzi Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr Opin Nephrol Hypertens 9 2 2000 143 147
51. P.O. Attman, O. Samuelsson, and P. Alaupovic Lipoprotein metabolism and renal failure Am J Kidney Dis 21 6 1993 573 592
52. O. Samuelsson, P.O. Attman, and C. Knight-Gibson Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency Nephrol Dial Transplant 9 11 1994 1580 1585
53. P. Alaupovic Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families Prog Lipid Res 30 2-3 1991 105 138
54. P.O. Attman, O. Samuelsson, and P. Alaupovic Progression of renal failure: role of apolipoprotein B-containing lipoproteins Kidney Int 52 Suppl 63 1997 98 101
55. J.B. Moberly, P.O. Attman, and O. Samuelsson Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia Miner Electrolyte Metab 25 4-6 1999 258 262
56. P.O. Attman, O.G. Samuelsson, and J. Moberly Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis Kidney Int 55 4 1999 1536 1542
57. O. Samuelsson, H. Mulec, and C. Knight-Gibson Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency Nephrol Dial Transplant 12 9 1997 1908 1915
58. H. Kapelrud, H.J. Bangstad, and K. Dahl-Jorgensen Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria BMJ 303 6804 1991 675 678
59. F.S. Nielsen, A.I. Voldsgaard, and M.A. Gall Apolipoprotein (a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy Diabetologia 36 5 1993 438 444
60. G. Bruno, P. Cavallo-Perin, and G. Bargero Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects Diabetes Care 19 1 1996 43 47
61. W.P. Battisti, J. Palmisano, and W.F. Keane Dyslipidemia in patients with type 2 diabetes. Relationships between lipids, kidney disease and cardiovascular disease Clin Chem Lab Med 41 9 2003 1174 1181
62. C. Zoccali, F. Mallamaci, and G. Tripepi Traditional and emerging cardiovascular risk factors in end-stage renal disease Kidney Int 63 Suppl 85 2003 S105 S110
63. E.G. Lowrie, and N.L. Lew Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 5 1990 458 482
64. W. Tschöpe, M. Koch, and B. Thomas Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia Nephron 64 3 1993 354 358
65. National Kidney Foundation K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease Am J Kidney Dis 41 Suppl 3 2003 S1 S91
66. R.N. Foley, and P.S. Parfrey Cardiovascular disease and mortality in ESRD J Nephrol 11 5 1998 239 245
67. C. Wanner, and V. Krane Non-high density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients Am J Kidney Dis 41 3 Suppl 1 2003 S72 S75
68. P.O. Attman, O. Samuelsson, and A.C. Johansson Dialysis modalities and dyslipidemia Kidney Int 63 Suppl 84 2003 S110 S112
69. V.M. Campese, S. Bianchi, and R. Bigazzi Hypertension, hyperlipidemia and microalbuminuria Contrib Nephrol 120 1997 11 21
70. G.A. Kaysen Hyperlipidemia of the nephrotic syndrome Kidney Int 39 Suppl 31 1991 S8 S15
71. W.F. Keane, J.V. St. Peter, and B.L. Kasiske Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int 42 Suppl 38 1992 S134-41
72. S.R. Newmark, C.F. Anderson, and J.V. Donadio Lipoprotein profiles in adult nephrotics Mayo Clin Proc 50 7 1975 359 364
73. I. Karådi, L. Romics, and G. Pålos Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin Clin Chem 35 10 1989 2121 2123
74. W.F. Keane Proteinuria: its clinical importance and role in progressive renal disease Am J Kidney Dis 35 4 Suppl 1 2000 S97 S105
75. J.P. Tolins, B.G. Stone, and L. Raij Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury Kidney Int 41 5 1992 1254 1261
76. J.F. Moorhead, M.K. Chan, and M. El Nahas Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease Lancet 2 8311 1982 1309 1311
77. W.F. Keane, W.S. Mulcahy, and B.L. Kasiske Hyperlipidemia and progressive renal disease Kidney Int 39 Suppl 31 1991 S41 S48
78. M. Tonelli, L. Moyé, F.M. Sacks for the Cholesterol and Recurrent Events (CARE) Trial Investigators Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 6 2003 1605 1613
79. B.H. Rovin, and L.C. Tan LDL stimulates mesangial fibronectin production and chemoattractant expression Kidney Int 43 1 1993 218 225
80. S. Klahr, G. Schreiner, and I. Ichikawa The progression of renal disease N Engl J Med 318 25 1988 1657 1666
81. L.M. Alderson, G. Endemann, and S. Lindsey LDL enhances monocyte adhesion to endothelial cells in vitro Am J Pathol 123 2 1986 334 342
82. R. Pai, M.A. Kirschenbaum, and V.S. Kamanna Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells Kidney Int 48 4 1995 1254 1262
83. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 5 2003 383 393
84. R. Collins, J. Armitage, and S. Parish Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 9411 2004 757 767
85. H.M. Colhoun, M.J. Thomason, and M.I. Mackness Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes Diabet Med 19 3 2002 201 211
86. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
87. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 1 2001 260 269
88. Y. Imai, H. Suzuki, and T. Saito The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group Clin Exp Hypertens 21 8 1999 1345 1355
89. M. Tonelli, L. Moye, and F.M. Sacks Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 2 2003 98 104
90. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5693 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
91. C. Baigent, and M. Landry Study of Heart and Renal Protection (SHARP) Kidney Int 63 Suppl 84 2003 S207 S210
92. Z.A. Massy, J.Z. Ma, and T.A. Louis Lipid-lowering therapy in patients with renal disease Kidney Int 48 1 1995 188 198
93. K.P. Harris, D.C. Wheeler, and C.C. Chong A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD Kidney Int 61 4 2002 1469 1474
94. S.L. Seliger, N.S. Weiss, and D.L. Gillen HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney Int 61 1 2002 297 304
95. G. Hufnagel, C. Michel, and F. Vrtovsnik Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis Nephrol Dial Transplant 15 5 2000 684 688
96. D. Saltissi, C. Morgan, and R.J. Rigby Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis Am J Kidney Dis 39 2 2002 283 290
97. O. Nishikawa, M. Mune, and M. Miyano Effect of simvastatin on the lipid profile of hemodialysis patients Kidney Int 56 Suppl 71 1999 S219 S221
98. E. Matthys, M. Schurgers, and G. Lamberigts Effect of simvastatin on the dyslipoproteinemia in CAPD patients Atherosclerosis 86 2-3 1991 183 192
99. H. Holdaas, B. Fellstrom, and A.G. Jardine Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 9374 2003 2024 2031
100. C. Wanner, V. Krane, and G. Ruf Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators Kidney Int 71 1999 S222 S226